Clinical Trials Logo

Oral Ulcer clinical trials

View clinical trials related to Oral Ulcer.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT05288478 Enrolling by invitation - Clinical trials for Epidermolysis Bullosa

Dose-ranging Study of Dentoxol® Mouthrinse for Managing Oral Symptoms in People With Epidermolysis Bullosa.

Start date: April 6, 2022
Phase: Phase 2
Study type: Interventional

Inherited Epidermolysis Bullosa (EB) is a disorder that causes skin fragility and blistering in skin and mucous membranes, including the mouth. Recurrent oral blisters and ulcer result in oral pain and discomfort. Dentoxol® is a mouthrinse that has anti-inflammatory, antimicrobial and analgesic effects. It has significant potential to reduce EB related oral symptoms. This study includes people living with Inherited Epidermolysis Bullosa aged 6 and above; and is aimed at determining the efficacy of two different dose regimens of Dentoxol mouthrinse in reducing oral symptoms.